Olgu Sunumu
BibTex RIS Kaynak Göster

Rheumatoid arthritis treatment strategies: Switch or swap?

Yıl 2021, , 42 - 43, 20.01.2021
https://doi.org/10.19161/etd.863621

Öz

Rheumatoid arthritis is the most common inflammatory disease in adults. Modifications for treatment
should be made until reaching the goals. Detailed studies should be planned for developing tailoring
therapies

Kaynakça

  • Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7.
  • Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15.
  • Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (6): 960-77.
  • Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68 (1): 1-25.
  • Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 6): vi28-36.
  • Acosta-Herrera M, González-Serna D, Martín J. The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis. J Clin Med 2019; 10; 8(6). pii: E826. doi: 10.3390/jcm8060826. Review

Romatoid artrit tedavi prensipleri: Neye geçiş yapalım?

Yıl 2021, , 42 - 43, 20.01.2021
https://doi.org/10.19161/etd.863621

Öz

Romatoid artrit erişkinde en sık görülen inflamatuar artrittir. Remisyon veya düşük hastalık aktivitesi
sağlanana kadar tedavi modifikasyonları yapılmalıdır. Gelecekte yapılacak daha kapsamlı çalışmalar
ile bireyselleştirilmiş tedavilerin geliştirilmesi mümkün olabilecektir.

Kaynakça

  • Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7.
  • Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15.
  • Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (6): 960-77.
  • Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68 (1): 1-25.
  • Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 6): vi28-36.
  • Acosta-Herrera M, González-Serna D, Martín J. The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis. J Clin Med 2019; 10; 8(6). pii: E826. doi: 10.3390/jcm8060826. Review
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Olgu Sunumu
Yazarlar

Gonca Karabulut 0000-0002-4408-8767

Zeynep Özbalkan Aşlar 0000-0001-5174-2221

Yayımlanma Tarihi 20 Ocak 2021
Gönderilme Tarihi 6 Nisan 2020
Yayımlandığı Sayı Yıl 2021

Kaynak Göster

Vancouver Karabulut G, Özbalkan Aşlar Z. Romatoid artrit tedavi prensipleri: Neye geçiş yapalım?. ETD. 2021:42-3.

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519